Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lyra Therapeutics (LYRA) Equity Ratio (2021 - 2025)

Lyra Therapeutics has reported Equity Ratio over the past 5 years, most recently at 0.3 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.3 for Q4 2025, down 269.84% from a year ago — trailing twelve months through Dec 2025 was 0.3 (down 269.84% YoY), and the annual figure for FY2025 was 0.3, down 269.84%.
  • Equity Ratio for Q4 2025 was 0.3 at Lyra Therapeutics, down from 0.1 in the prior quarter.
  • Over the last five years, Equity Ratio for LYRA hit a ceiling of 0.93 in Q1 2021 and a floor of 0.3 in Q4 2025.
  • Median Equity Ratio over the past 5 years was 0.63 (2021), compared with a mean of 0.48.
  • Biggest five-year swings in Equity Ratio: skyrocketed 43.33% in 2023 and later tumbled 269.84% in 2025.
  • Lyra Therapeutics' Equity Ratio stood at 0.63 in 2021, then grew by 17.41% to 0.73 in 2022, then fell by 14.61% to 0.63 in 2023, then plummeted by 72.13% to 0.17 in 2024, then tumbled by 269.84% to 0.3 in 2025.
  • The last three reported values for Equity Ratio were 0.3 (Q4 2025), 0.1 (Q3 2025), and 0.03 (Q2 2025) per Business Quant data.